Zakowski W, Zawistowski P
Brain Struct Funct. 2023; 228(6):1379-1398.
PMID: 37378855
PMC: 10335970.
DOI: 10.1007/s00429-023-02673-4.
Laszlo B, Kertes E, Ollmann T, Peczely L, Kovacs A, Karadi Z
Biomedicines. 2022; 10(12).
PMID: 36551894
PMC: 9775557.
DOI: 10.3390/biomedicines10123138.
Purves-Tyson T, Brown A, Weissleder C, Rothmond D, Weickert C
Mol Brain. 2021; 14(1):96.
PMID: 34174930
PMC: 8235806.
DOI: 10.1186/s13041-021-00805-7.
Shin S, Kaiser E, West F
Front Physiol. 2021; 11:592950.
PMID: 33488396
PMC: 7818780.
DOI: 10.3389/fphys.2020.592950.
Sanger G, Andrews P
Front Pharmacol. 2018; 9:913.
PMID: 30233361
PMC: 6131675.
DOI: 10.3389/fphar.2018.00913.
Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients.
Ouyang Q, Gong X, Xiao H, Zhou J, Xu M, Dai Y
Mol Cancer. 2015; 14:21.
PMID: 25644759
PMC: 4351837.
DOI: 10.1186/s12943-015-0290-8.
Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.
Chou S, Davis C, Jones S, Li M
Pharmacol Biochem Behav. 2014; 128:78-88.
PMID: 25433325
PMC: 4277720.
DOI: 10.1016/j.pbb.2014.11.015.
The role of substance P in depression: therapeutic implications.
Schwarz M, Ackenheil M
Dialogues Clin Neurosci. 2011; 4(1):21-9.
PMID: 22033776
PMC: 3181667.
The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.
Pantaleo N, Chadwick W, Park S, Wang L, Zhou Y, Martin B
CNS Neurol Disord Drug Targets. 2010; 9(5):627-35.
PMID: 20632965
PMC: 2967650.
DOI: 10.2174/187152710793361504.
The role of neurotensin in central nervous system pathophysiology: what is the evidence?.
St-Gelais F, Jomphe C, Trudeau L
J Psychiatry Neurosci. 2006; 31(4):229-45.
PMID: 16862241
PMC: 1488904.
Expression of five somatostatin receptor mRNAs in the human brain and pituitary.
Thoss V, Perez J, Probst A, Hoyer D
Naunyn Schmiedebergs Arch Pharmacol. 1996; 354(4):411-9.
PMID: 8897442
DOI: 10.1007/BF00168430.
Ontogeny of GABA-immunoreactive cells in the primate cerebellar cortex: comparison with somatostatin-immunoreactivity.
Yamashita A, Hayashi M
Anat Embryol (Berl). 1996; 194(3):215-22.
PMID: 8849668
DOI: 10.1007/BF00187132.
Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.
Fischer J, Tobler P, Kaufmann M, Born W, Henke H, Cooper P
Proc Natl Acad Sci U S A. 1981; 78(12):7801-5.
PMID: 6950419
PMC: 349359.
DOI: 10.1073/pnas.78.12.7801.
An immunohistochemical study of somatostatin and neurotensin positive neurons in the septal nuclei of the rat brain.
Kohler C, Eriksson L
Anat Embryol (Berl). 1984; 170(1):1-10.
PMID: 6148028
DOI: 10.1007/BF00319452.
Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain.
SCHOTTE A, Leysen J, Laduron P
Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(4):400-5.
PMID: 3022160
DOI: 10.1007/BF00500016.
Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain.
Herve D, Tassin J, Studler J, Dana C, Kitabgi P, Vincent J
Proc Natl Acad Sci U S A. 1986; 83(16):6203-7.
PMID: 3016745
PMC: 386468.
DOI: 10.1073/pnas.83.16.6203.
HPLC analysis of somatostatin related peptides in putamen of Huntington's disease patients.
Sperk G, Reynolds G, Riederer P
J Neural Transm. 1987; 69(1-2):153-60.
PMID: 2953863
DOI: 10.1007/BF01244106.
Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immunohistochemical study.
Zech M, Roberts G, Bogerts B, Crow T, Polak J
Acta Neuropathol. 1986; 71(3-4):259-66.
PMID: 2948368
DOI: 10.1007/BF00688048.
Somatostatin-14-like immunoreactive neurons and fibres in the human olfactory bulb.
Ohm T, Braak E, Probst A
Anat Embryol (Berl). 1988; 179(2):165-71.
PMID: 2906788
DOI: 10.1007/BF00304698.
Postmortem stability of somatostatin in brain tissue.
Cooper P, Rahman Q, Phillips T, Tu J
Neurochem Res. 1988; 13(6):513-5.
PMID: 2900480
DOI: 10.1007/BF00973289.